drugset
drugset / Trial / NCT01079767

Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis

NCT01079767 ↗

Phase 2 Terminated 6 enrolled Federation Francophone de Cancerologie Digestive
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well temsirolimus works in treating patients with advanced liver cancer and cirrhosis.

Timeline

Start
2010-01
Primary completion
2010-12
Completion
—

Outcome

Outcome not reported

Stopped: “The study treminated early according to DSMB recommendantions”

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule — Intravenous

Indications

liver cancer